Skip to main content
bioMérieux logo

bioMérieux — Investor Relations & Filings

Ticker · BIM ISIN · FR0013280286 LEI · 549300AK8Y0LBIQ4T071 PA Manufacturing
Open in API
Filings indexed 414 across all filing types
Latest filing 2021-06-29 Regulatory Filings
Country FR France
Listing PA BIM

About bioMérieux

https://www.biomerieux.com/

bioMérieux is a global leader in the field of in vitro diagnostics, providing solutions that determine the source of disease and contamination. The company develops and manufactures diagnostic systems, reagents, and software for both clinical and industrial applications. In the clinical sector, its products are used for diagnosing infectious diseases, managing sepsis, combating antimicrobial resistance, and supporting cancer screening and cardiovascular emergencies. For industrial markets, bioMérieux offers microbiological control solutions to ensure the safety and quality of agri-food, pharmaceutical, and cosmetic products. These technologies provide rapid and reliable data to help healthcare professionals and industrial quality control managers make critical decisions that improve patient outcomes and ensure consumer safety.

Recent filings

Filing Released Lang Actions
Lutte contre l'antibiorésistance : bioMérieux et Specific Diagnostics annoncent un accord de distribution co-exclusive en Europe du système d’antibiogramme rapide SPECIFIC REVEAL®
Regulatory Filings Classification · 95% confidence The document is a press release dated June 29, 2021, announcing a co-exclusive distribution agreement between bioMérieux and Specific Diagnostics for the REVEAL rapid antibiogram system in Europe. It details a business partnership, investment, and product integration. This type of announcement, which details strategic business developments, partnerships, or significant corporate actions (like an investment/financing component related to a partnership), fits best under Capital/Financing Update (CAP) if the focus is on the investment, or Regulatory Filings (RNS) if it's a general corporate announcement not covered elsewhere. Since it explicitly mentions bioMérieux investing $10 million via a Convertible Promissory Note and acquiring an 8% stake, it strongly relates to capital structure changes or financing activities. However, the primary focus is the distribution agreement and product launch synergy. Given the options, this is a significant corporate event announcement. It is not an ER, CT, 10-K, or IR. It is not a DIRS, DIV, or NAV. It is a strategic business announcement. While it contains a financing element ($10M investment), the core is the distribution deal. In the context of standard SEC/Exchange filings, major partnership announcements that aren't earnings or mandatory reports often fall under general regulatory announcements. Since 'CAP' is defined as 'Updates on company fundraising, financing activities, or capital structure changes,' and this includes a $10M investment, CAP is a strong candidate. However, if the document is primarily a press release about a commercial agreement, RNS (Regulatory Filings / general announcement) is often used for non-standard press releases. Given the explicit mention of a $10 million investment via a Convertible Promissory Note, classifying it as a Capital/Financing Update (CAP) is justifiable due to the direct financial transaction described, even though it's embedded in a partnership announcement. I will lean towards CAP due to the specific financial transaction mentioned, but RNS is a close second for a general press release.
2021-06-29 French
bioMérieux launches EPISEQ® SARS-COV-2, a cloud-based software application for the epidemiological surveillance of SARS-CoV-2 variants
Regulatory Filings Classification · 95% confidence The document is a press release dated June 24th, 2021, announcing the launch of a new software application, EPISEQ® SARS-COV-2, by bioMérieux. It details the product's features, purpose (epidemiological surveillance of SARS-CoV-2 variants), and includes quotes from executives and boilerplate information about the company. This type of announcement, which is not a formal regulatory filing (like 10-K, IR, or ER) but rather a general corporate update about a new product/service, fits best under the general 'Regulatory Filings' (RNS) category as a miscellaneous corporate announcement, or potentially a specialized 'Investor Presentation' (IP) if it were structured as a deck, but given the press release format, RNS is the most appropriate general category for non-standard announcements not covered by other specific codes. It is not an Earnings Release (ER), Interim Report (IR), or a specific legal/governance document.
2021-06-24 English
bioMérieux lance EPISEQ® SARS-COV-2, une application logicielle sur le cloud pour la surveillance épidémiologique des variants du SARS-CoV-2
Regulatory Filings Classification · 90% confidence The document is a press release dated June 24, 2021, announcing the launch of a new software application, EPISEQ® SARS-COV-2, by bioMérieux. It details the product's features, purpose (epidemiological surveillance of SARS-CoV-2 variants), and provides background information on the company and its platform. This type of announcement, which is a general corporate update about a new product or service launch, does not fit neatly into the specific financial filing categories like 10-K, ER, or IR. Since it is a general corporate announcement that doesn't fit the other specific categories (like M&A, Dividend, Management Change, etc.), the most appropriate fallback category is Regulatory Filings (RNS), which serves as a general category for miscellaneous regulatory or significant corporate announcements not covered elsewhere.
2021-06-24 French
Mai 2021 - Déclaration capital et droits de vote
Share Issue/Capital Change Classification · 95% confidence The document is titled 'Informations mensuelles relatives au nombre total de droits de vote et d'actions prévues par l'article L. 233-8 II du code de commerce et l'article 223-16 du règlement général de l'Autorité des marchés financiers'. This explicitly indicates a monthly disclosure regarding the total number of voting rights and shares, which is a regulatory requirement in France (AMF). This type of filing, detailing changes in total shares and voting rights, is most closely aligned with notifications concerning significant share ownership changes or general regulatory updates on capital structure, but the specific nature points towards a mandatory disclosure related to share capital and voting rights. Reviewing the definitions: - It is not an Annual Report (10-K), Interim Report (IR), or Earnings Release (ER). - It is not a Director's Dealing (DIRS) as it reports total company shares, not individual transactions. - It is not a Dividend Notice (DIV). - It is a specific regulatory disclosure about the total number of shares and voting rights as of a specific date (31/05/2021). This type of filing, reporting on the total number of shares and voting rights as mandated by French commercial code and AMF regulations, is a specific type of regulatory disclosure. While it touches upon share capital, it is not a general capital change announcement (SHA) but a mandatory periodic report on voting power. Given the options, it fits best under the general 'Regulatory Filings' (RNS) as a specific, recurring regulatory disclosure that doesn't map perfectly to the other specialized categories like DIRS or DIV, although it is related to share capital. However, let's re-evaluate against 'Major Shareholding Notification' (MRQ). MRQ is defined as 'Notification of changes in significant share ownership levels (crossing thresholds)'. While this document reports the *total* number of shares/votes, it is often published alongside or as a result of changes in major holdings, or simply as a mandatory monthly update on the total capital base. Since the document explicitly reports the total number of shares and voting rights as required by specific articles (L. 233-8 II and 223-16), it is a mandatory disclosure related to the capital structure and shareholder rights. In many jurisdictions, mandatory monthly disclosures of total voting rights are classified separately or fall under general regulatory filings. Given the provided list, RNS (Regulatory Filings - fallback) is the safest classification for a specific, non-standard regulatory report. If we must choose a more specific one, it relates to the structure of ownership, but it is not a notification *of* a major shareholder crossing a threshold, but a statement of the *total* base. Therefore, RNS is the most appropriate fallback for this specific French regulatory filing type.
2021-06-10 French
AG 2021 - Descriptif du programme de rachat d'actions
Delisting Announcement Classification · 99% confidence The document is titled "DESCRIPTIF DU PROGRAMME DE RACHAT D'ACTIONS" (Description of the Share Buyback Program) and details the terms, objectives (liquidity, employee stock plans, capital reduction), duration, and current holdings related to a share repurchase program authorized by the General Meeting. This directly relates to the company's own shares being transacted. This aligns perfectly with the definition for 'Transaction in Own Shares' (POS), which covers share repurchase programs.
2021-05-20 French
AG 2021 - Descriptif du programme de rachat d'actions
Share Issue/Capital Change Classification · 99% confidence The document explicitly details the 'DESCRIPTION OF THE NEW SHARE BUYBACK PROGRAM' authorized by the Annual General Meeting. It outlines the maximum stake, price, cost, objectives (liquidity, hedging employee plans, capital reduction, acquisitions), and the term of the program. This content directly relates to the company's actions regarding its own shares, specifically repurchases or buybacks. This aligns perfectly with the definition for 'Transaction in Own Shares' (POS). Although it references the AGM authorization, the core subject is the execution plan for the buyback, not the AGM results (DVA) or the general AGM materials (AGM-R).
2021-05-20 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.